acv 1 results mid august, page-9

I'm not surprised that the initial reaction of some investors is totake their money out of the stock right now, to get back in at any opprotune time in the next two weeks. But long run, I agree with KOKO, this trial was not POWERED for efficacy, but there has always been an announced intent to look for indications of efficacy.

If they have good indications of efficacy from all 40 patients, then it would be useful to know in cuantitative terms just how meaningful that might be in the context of the study design.

There may be other issues that also need solid independent verification and authentication. But, you wouldn't go to the trouble and expense of taking this step on bad data.

Once the initial sell foff is over, the stock will continue its rally.